ArticleFrontiers in oncology2025

Adjuvant tyrosine kinase inhibitors plus anti-PD-1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection.

Jiaxin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.